Global Psychedelic Drugs Market Size and Forecast to 2029: Revenue, Growth, and Trends

Uncover key drivers, emerging technologies, and competitive movements shaping the psychedelic drugs market from 2025–2034 with trusted insights from The Business Research Company

How Big Is The Psychedelic Drugs Market Size Today And What Will Its Value Be At The End Of 2029?

The antiobesity market size has shown robust growth over recent years. It is projected to increase from $3.74 billion in 2024 to $4.1 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.7%. Historically, this expansion has been driven by increasing obesity prevalence, enhanced awareness and education, evolving lifestyle changes, and various government initiatives.

The antiobesity market is anticipated to show considerable growth over the next few years, with its size projected to reach $5.94 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.7%. This expansion during the forecast period is primarily due to market expansion and globalization. Key trends expected in this period involve enhanced research and development, the adoption of patient-centric approaches, increased insurance coverage, continuous technological advancements, the integration of digital health and telemedicine, the emergence of novel drug therapies, further advancements in bariatric surgery, the availability of over-the-counter (OTC) solutions, effective behavioral interventions, and innovative nutritional and weight management applications.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3403&type=smp

Which Key Drivers Are Powering Growth In The Psychedelic Drugs Market?

Obesity represents a critical public health challenge worldwide, with its global prevalence rate steadily climbing annually. For instance, in May 2022, the World Obesity Atlas, a UK-based organization focused on obesity, projected that over 1 billion individuals globally are estimated to suffer from obesity by 2030. This escalation is largely due to increased intake of processed and unhealthy foods, insufficient physical activity, and a lack of understanding regarding the risks associated with obesity. Consequently, the future demand for anti-obesity drugs is set to increase, thus fostering market expansion.

Which Segment Categories Are Driving Maximum Growth In The Psychedelic Drugs Market?

The antiobesity market covered in this report is segmented –

1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs

2) By Type: Prescription Drugs (Rx), OTC Drugs

3) By Medication: Monotherapies, Polytherapies

Subsegments:

1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin

2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide

What Key Trends Are Driving Growth In The Psychedelic Drugs Market?

Major companies operating in the anti-obesity drugs market are concentrating on developing novel products, such as Mounjaro (tirzepatide), to offer dependable services to customers. Mounjaro (tirzepatide) functions as an anti-obesity medication for the treatment of adults experiencing obesity or those who are overweight with associated weight-related health conditions. For instance, in October 2022, Eli Lilly and Company, a US-based pharmaceutical company, introduced Mounjaro (tirzepatide), which received fast track designation approval from the Food and Drug Administration (FDA), a US-based federal agency. Mounjaro (tirzepatide) is an injectable anti-obesity drug designed to assist individuals struggling with obesity in achieving their weight loss goals. This medication is also prescribed for adults with type 2 diabetes, to be used alongside diet and exercise, for improving blood sugar (glucose) levels.

Who Are The Leading Companies Driving The Psychedelic Drugs Market?

Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Which Region Holds The Largest Share In The Psychedelic Drugs Market Today?

North America was the largest region in the anti-obesity market in 2024. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=3403&type=smp

Browse Through More Reports Similar to the Global Psychedelic Drugs Market 2025, By The Business Research Company

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Smart Pills Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-pills-global-market-report

Organ On Chip Market 2025

https://www.thebusinessresearchcompany.com/report/organ-on-chip-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795